Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Rhea-AI Summary
Kymera Therapeutics (NASDAQ: KYMR) will report fourth quarter and full year 2025 financial results on February 26, 2026 and will host a video conference call and webcast at 8:30 a.m. ET.
Investors can register to join the live video call or view the livestreamed webcast via the company website; a replay will be archived after the event.
Positive
- None.
Negative
- None.
News Market Reaction – KYMR
In the Feb 19 session, KYMR gained 1.63%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 05 | Earnings/date scheduling | Positive | +0.1% | Announced date and time for KT-621 BroADen Phase 1b topline results release. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited history for 'earnings date' type news shows small, aligned price moves around scheduling announcements.
The company has previously used similar announcements to flag upcoming catalysts. On Dec 5, 2025, Kymera set expectations for KT-621 BroADen Phase 1b topline data with an “earnings date”-tagged release, which saw a modest 0.09% positive move. Today’s notice of the Feb 26, 2026 Q4 and full-year 2025 results date fits that pattern of scheduling-focused communication rather than new data disclosure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report fourth quarter and full year 2025 financial results on February 26, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.
To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
| Investor and Media Contact: Justine Koenigsberg Vice President, Investor Relations investors@kymeratx.com media@kymeratx.com 857-285-5300 |
